![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 31/502 | |
A61K 9/22 | |||
A61K 9/52 | |||
A61P 35/00 | |||
A61K 9/16 | |||
A61K 9/20 | |||
A61K 9/24 | |||
A61K 9/50 |
(11) | Number of the document | 3556369 |
(13) | Kind of document | T |
(96) | European patent application number | 17880064.5 |
Date of filing the European patent application | 2017-12-15 | |
(97) | Date of publication of the European application | 2019-10-23 |
(45) | Date of publication and mention of the grant of the patent | 2021-04-14 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/CN2017/116475 |
Date | 2017-12-15 |
(87) | Number | WO 2018/108152 |
Date | 2018-06-21 |
(30) | Number | Date | Country code |
201611168797 | 2016-12-16 | CN |
(72) |
GAN, Yong, CN
ZHU, Quanlei, CN
GUO, Shiyan, CN
ZHU, Chunliu, CN
|
(73) |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
555 Zu Chong Zhi Road Zhangjiang Hi-Tech Park Pudong New District, Shanghai 201203,
CN
|
(54) | OLAPARIB ORAL SUSTAINED AND CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND USES THEREOF |
OLAPARIB ORAL SUSTAINED AND CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND USES THEREOF |